89bio, Inc. ETNB
Institutional shares held
125 Million
78.7K
calls
979K
puts
Total value of holdings
$1.41B
$889K
calls
$11.1M
puts
Market Cap
$509M
46,484,500
Shares Out.
Institutional ownership
267.9%
# of Institutions
173
We take great care to ensure that the data presented and summarized in this overview for 89bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETNB
View all-
Janus Henderson Group PLC London, X016.5MShares$181 Million0.07% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$155 Million1.76% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.2MShares$112 Million3.26% of portfolio
-
Rtw Investments, LP New York, NY7.48MShares$81.8 Million0.94% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$76.8 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.48MShares$70.9 Million2.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.69MShares$62.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.73MShares$51.7 Million0.01% of portfolio
-
Bvf Inc San Francisco, CA4.33MShares$47.4 Million1.24% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.1MShares$44.9 Million0.46% of portfolio
Latest Institutional Activity in ETNB
Top Purchases
Top Sells
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Transactions at ETNB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,050
-0.33%
|
$10,500
$10.57 P/Share
|
|
Feb 17
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
780
-0.29%
|
$7,800
$10.57 P/Share
|
|
Feb 17
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,249
-0.38%
|
$32,490
$10.57 P/Share
|
|
Feb 17
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,050
-0.3%
|
$10,500
$10.57 P/Share
|
|
Feb 09
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,817
-1.18%
|
$41,987
$11.41 P/Share
|
|
Feb 09
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
3,793
-1.09%
|
$41,723
$11.41 P/Share
|
|
Feb 09
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,828
-1.4%
|
$42,108
$11.41 P/Share
|
|
Feb 09
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,946
-1.02%
|
$98,406
$11.41 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Indirect |
8,750
+37.23%
|
$78,750
$9.6 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-0.95%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+18.53%
|
-
|
|
Feb 01
2025
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-1.2%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+22.37%
|
-
|
|
Feb 01
2025
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,338
-1.02%
|
$30,042
$9.6 P/Share
|
|
Feb 01
2025
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+19.65%
|
-
|
|
Feb 01
2025
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,598
-1.09%
|
$86,382
$9.6 P/Share
|
|
Feb 01
2025
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
412,000
+21.07%
|
-
|
|
Feb 01
2025
|
Francis Willard Sarena Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,750
+40.57%
|
-
|
|
Jan 30
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
5,714,285
+22.61%
|
$45,714,280
$8.75 P/Share
|
|
Jan 22
2025
|
Charles Mc Wherter |
BUY
Open market or private purchase
|
Direct |
10,000
+28.57%
|
$60,000
$6.71 P/Share
|
Last 12 Months Summary
Buy / Acquisition
9.28M
Shares
From
10
Insiders
| Open market or private purchase | 7.1M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 1.41M shares |
| Grant, award, or other acquisition | 746K shares |
| Exercise of conversion of derivative security | 25K shares |
Sell / Disposition
449K
Shares
From
9
Insiders
| Payment of exercise price or tax liability | 67.5K shares |
|---|---|
| Open market or private sale | 96.1K shares |
| Grant, award, or other acquisition | 285K shares |